Pfizer discontinues TRU-015

Trubion Pharmaceuticals Inc. (NASDAQ:TRBN) said partner Pfizer Inc. (NYSE:PFE) discontinued development of TRU-015 after it missed the primary endpoint in a Phase IIb trial to treat rheumatoid arthrit...